Actively Recruiting
Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-05-29
150
Participants Needed
1
Research Sites
259 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire, Amiens
Lead Sponsor
H
Hospices Civils de Lyon
Collaborating Sponsor
AI-Summary
What this Trial Is About
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed neurodevelopmental disorder in childhood. Patients with ADHD present inattention, impulsivity and hyperactivity causing severe impairments on academic achievement, social and professional life and daily functioning. Medications are effective in a majority of children with ADHD, but about 30% do not respond or tolerate stimulants, and some parents refuse pharmacological treatments.Transcranial Direct Current Stimulation is a safe and non-invasive technique of brain stimulation used in several neurological and psychiatric disorders, and recently in ADHD. In patients with ADHD, tDCS stimulations targeted frontal regions improve executive and attentional functioning and daily life symptoms. The objective of this project is to evaluate the efficacy of tDCS (vs sham) during cognitive-remediation exercises on ADHD symptoms (inattention, impulsivity and hyperactivity as defined by DSM-5) in children with ADHD between 7 and 14 years of age.
CONDITIONS
Official Title
Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged 7 to 14 years with sufficient compliance to participate
- Parent or legal guardian must provide signed informed consent; children must provide assent if able
- Diagnosis of ADHD with combined presentation based on DSM-5, ADHD Rating Scale, and clinical evaluation
- Minimum ADHD Rating Scale total score of 32 at enrollment
- Minimum Clinical Global Impression score of 4 at enrollment
- Age-appropriate intellectual level with a Full IQ above 80 on WISC-5
- Children who stopped stimulant medication due to adverse effects may join after a washout period of at least 7 days
You will not qualify if you...
- Presence of neurological conditions such as epilepsy, cerebral palsy, or brain injury sequelae
- Comorbid psychiatric disorders including conduct disorders, autism, severe OCD, mood disorders, bipolar illness, psychosis, or substance abuse
- Current use of stimulant or psychotropic medications, benzodiazepines, antidepressants, hypnotics, or melatonin
- Previous non-response to stimulant medication
- Severe sleep disorders
- Any contraindication to receiving tDCS treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Amiens
Amiens, France, 80480
Actively Recruiting
Research Team
P
Patrick BERQUIN, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here